RenovoRx Reports Solid First Full Year of RenovoCath Commercialization

Company Generates $1.1 Million in 2025 Revenue, Strengthens Balance Sheet, and Advances Phase III TIGeR-PaC Trial

Mar. 31, 2026 at 3:33am

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image of a sleek, polished medical device made of stainless steel and glass, symbolizing the innovative RenovoCath technology developed by RenovoRx for targeted cancer treatment.RenovoRx's innovative RenovoCath device represents a new frontier in targeted cancer treatment, delivering precision and sophistication in a polished, high-tech design.Mountain View Today

RenovoRx, a life-sciences company developing innovative targeted oncology therapies, announced its financial results for the full year and fourth quarter of 2025. The company generated over $1 million in revenue from its first full year of RenovoCath commercialization, reflecting strong initial physician adoption and demand. RenovoRx also strengthened its balance sheet with a $10 million financing and continues to advance its pivotal Phase III TIGeR-PaC clinical trial.

Why it matters

RenovoRx's successful commercialization of its RenovoCath device and progress in its TIGeR-PaC trial demonstrate the company's ability to drive growth and shareholder value through its innovative targeted oncology platform. The RenovoCath revenue and expanding commercial footprint validate physician interest in the device, while the TIGeR-PaC trial progress brings RenovoRx closer to a potential new drug application submission.

The details

In 2025, RenovoRx generated $1.1 million in revenue from RenovoCath sales, driven by new cancer centers adopting the device and repeat orders from existing customers. The company also learned valuable lessons about commercial trends, activation timelines, and customer preferences to help drive further growth in 2026 and beyond. RenovoRx's network of active commercial cancer center clients continues to expand, with 12 centers currently utilizing RenovoCath and 21 additional centers evaluating or preparing to activate the device. The company also strengthened its balance sheet with a $10 million financing, providing $13 million in cash to fund operations. Separately, RenovoRx's pivotal Phase III TIGeR-PaC trial evaluating intra-arterial delivery of gemcitabine via RenovoCath remains on track, with 104 patients randomized and 72 events observed as of March 2026. The company anticipates completing enrollment by mid-2026 and reporting final data in 2027.

  • In 2025, RenovoRx generated $1.1 million in revenue from RenovoCath sales.
  • As of February 2026, 12 U.S. cancer centers are utilizing RenovoCath, and 21 additional centers are evaluating the device, have completed evaluation, or are preparing for activation.
  • As of March 24, 2026, 104 patients have been randomized in the TIGeR-PaC trial, with 72 events observed.
  • RenovoRx anticipates completing enrollment in the TIGeR-PaC trial by the middle of 2026.
  • Final data from the TIGeR-PaC trial is anticipated in 2027.

The players

Shaun Bagai

Chief Executive Officer of RenovoRx.

Mark Voll

Chief Financial Officer of RenovoRx, who joined the company in February 2026 to support commercial growth.

RenovoCath

A patented, FDA-cleared drug-delivery device developed by RenovoRx.

TIGeR-PaC Trial

RenovoRx's ongoing Phase III clinical trial evaluating intra-arterial delivery of gemcitabine via the RenovoCath device for the treatment of locally advanced pancreatic cancer.

TAMP (Trans-Arterial Micro-Perfusion) Therapy Platform

RenovoRx's therapy platform enabled by the RenovoCath device for targeted drug delivery.

Got photos? Submit your photos here. ›

What they’re saying

“2025 marked a key year as it was our first full year of RenovoCath commercialization, generating over $1 million in revenue and reflecting strong initial physician adoption and demand in a handful of active commercial cancer centers. We also learned many valuable lessons to finalize our go-to-market strategy that we are implementing and building out a team to drive commercial growth in 2026 and beyond.”

— Shaun Bagai, Chief Executive Officer of RenovoRx

“We strongly believe we now have the funding, business plan, leadership, and infrastructure to propel execution across all of our activities as we drive towards important milestones, including breakeven operations and trial data.”

— Shaun Bagai, Chief Executive Officer of RenovoRx

What’s next

RenovoRx's goal is to transition the 17 cancer centers that have used RenovoCath as part of the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026 after completion of TIGeR-PaC enrollment.

The takeaway

RenovoRx's successful first full year of RenovoCath commercialization, strengthened balance sheet, and progress in its pivotal TIGeR-PaC trial demonstrate the company's ability to drive growth and shareholder value through its innovative targeted oncology platform. The company is well-positioned to scale its commercial efforts and advance its clinical development programs in 2026 and beyond.